1786 — Scivision Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Scivision Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	116	174	210	292	185
Depreciation
Amortisation
Non-Cash Items	5.45	-35.7	-11.5	-21	-10.5
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-76	-21.7	10.3	-66	-131
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	98.5	178	272	270	124
Capital Expenditures	-25.8	-15	-14.7	-34.8	-102
Purchase of Fixed Assets
Other Investing Cash Flow Items	-51.2	64.6	-199	132	-41.2
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-77	49.6	-213	97.5	-143
Financing Cash Flow Items	—	0.006	0	0.164	0
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Debt
Cash from Financing Activities	240	-300	-135	-173	159
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	262	-71.9	-75.9	195	140